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ABSTRACT

INTRODUCTION

The drug–gene interaction database (DGIdb, www.
dgidb.org) consolidates, organizes and presents
drug–gene interactions and gene druggability information from papers, databases and web resources.
DGIdb normalizes content from 30 disparate sources
and allows for user-friendly advanced browsing,
searching and filtering for ease of access through
an intuitive web user interface, application programming interface (API) and public cloud-based server
image. DGIdb v3.0 represents a major update of the
database. Nine of the previously included 24 sources
were updated. Six new resources were added, bringing the total number of sources to 30. These updates and additions of sources have cumulatively resulted in 56 309 interaction claims. This has also substantially expanded the comprehensive catalogue of
druggable genes and anti-neoplastic drug–gene interactions included in the DGIdb. Along with these
content updates, v3.0 has received a major overhaul
of its codebase, including an updated user interface,
preset interaction search filters, consolidation of interaction information into interaction groups, greatly
improved search response times and upgrading the
underlying web application framework. In addition,
the expanded API features new endpoints which allow users to extract more detailed information about
queried drugs, genes and drug–gene interactions, including listings of PubMed IDs, interaction type and
other interaction metadata.

The drug–gene interaction database (DGIdb, www.dgidb.
org) was first released in 2013 to consolidate drug–gene interactions and potentially druggable genes into a single resource with a powerful interface to query these data (1).
DGIdb 2.0 was released in 2016 and featured substantial
content updates, a more intuitive user interface and the
inclusion of an application programming interface (API)
(2). Despite the success of the DGIdb, 2.0 became outdated in several ways. New sources have become available
since 2.0’s release and many existing sources within the
database required updates. The notion of grouping drug
claims (an assertion of a drug concept by a constituent resource) to match a canonical drug source (PubChem compounds), and grouping gene claims (an assertion of a gene
concept by a constituent resource) to a canonical gene
source (NCBI Entrez Gene) was described in the 2.0 paper (3,4). In brief, grouping allows the DGIdb to relate disparate representations of a gene or drug concept through
a core entity, or group. As the database grew, the grouping success rates dropped and new classes of drugs were
not fully represented in the search results. Additionally,
while the DGIdb grouped drug and gene claims, interactions were still reported at the claim level, with no concept of interaction groups. Furthermore, the initial API that
was released alongside 2.0 had limited endpoints that prevented users from extracting additional information about
their queried drug–gene interactions, such as PubMed IDs
(PMIDs) supporting the interactions and other interaction
metadata. Finally, the DGIdb has grown enormously since
its initial publication in 2013, and as a result, interaction
searches had become significantly slower. This new release
addresses these limitations, providing an improved user interface, quicker response times for searches and new meth-
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ods for accessing and incorporating the DGIdb into bioinformatics workflows.
EXPANDED CONTENT

NEW FEATURES AND ENHANCEMENTS
A major feature added in 3.0 is a user-selectable series of
preset filters. These allow users to select drug–gene interactions that align with some of the most common search
use cases. While it was possible for a user to filter on some
of the following attributes in 2.0, these concepts have now
been structured as stand-alone filters that can help focus
a user’s search results with a single click. The filters currently include FDA-approved drugs, anti-neoplastic drugs,
immunotherapy drugs, clinically actionable genes, genes included in the druggable genome definition and drug resistant genes. FDA approval status is extracted from ChEMBL
v23 (current as of this writing) (14). Anti-neoplastic drugs
are defined by inclusion in an anti-neoplastic drug–gene interaction source (e.g. My Cancer Genome), or as a drug
with an anti-neoplastic attribute from its constituent source.
Immunotherapy drugs are defined as any drug with an attribute of ‘immunosuppressive agent’, ‘immunomodulatory
agent’ or ‘immunostimulant’. Clinically actionable genes are
genes that constitute the DGIdb ‘clinically actionable’ gene
category, and by definition is used to inform clinical action (e.g. the Foundation One diagnostic gene panels). Similarly, druggable genome genes are genes listed in the DGIdb
‘druggable genome’ gene category (8,11,13,15–19). Drug resistance genes are defined by the Gene Ontology as genes
that confer drug resistance or susceptibility (GO identifier
0042493), and are maintained in the DGIdb through the
‘drug resistance’ gene category (13). To incorporate these
new filters, we have redesigned the data model, expanded
the definition of the druggable genome and restructured the
user interface (UI) to include a redesigned search form and
results interface. The UI also now features drug, gene and
interaction views to leverage the new grouping strategies
and preset filters.
Since the last release, several changes have been made to
the drug grouping strategy to improve overall grouping percentages. We have added support for fuzzy searching when
grouping if direct matches to drug groups are not found, en-
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For 3.0, there has been a substantial expansion of the content of the database through the addition of new sources
and the updating of existing sources. Six new sources have
been added, which brings the total number of sources represented by the DGIdb to 30. Three of these new sources provide drug–gene interactions from prominent expert-curated
databases of clinically actionable variants similar to the
CIViC and Clearity Foundation sources, already included
in the DGIdb (Supplementary Table S1) (5). These include
the Precision Oncology Knowledge Base (OncoKB), cancer genome interpreter (CGI) and The Jackson Laboratory Clinical Knowledgebase (CKB) (Supplementary Table S1) (6,7). From these three new sources, 2822 new interaction claims were added. These sources were added as
anti-neoplastic interaction sources, resulting in an 36.7%
increase in anti-neoplastic drugs. Drug–gene interactions
were also added from the United States Food and Drug
Administration (FDA) Pharmacogenomics website and the
National Cancer Institute (NCI) Cancer Gene Index, resulting in an additional 276 and 6231 interaction claims, respectively (Supplementary Table S1). In addition to these
sources, the existing druggable gene category sources were
expanded with data extracted from a new druggable genome
paper that used computational approaches to identify druggable genes from genome-wide association studies (Supplementary Table S2) (8). The inclusion of this source into
the DGIdb results in an additional 2300 potentially druggable genes, a 58% increase from 2.0 (Figure 1). Notably,
this independent definition of the druggable genome almost
completely encapsulates many other gene categories (e.g. kinases, G-protein coupled receptors) that are expected to be
good drug targets (Supplementary Figure S1).
As the DGIdb has matured, maintaining current representations of existing sources has become increasingly important relative to identifying new interaction sources. Curated updates of drug–gene interaction data from My Cancer Genome and the targeted and biologic therapies for
non-small-cell lung cancer (TALC) have occurred, resulting
in moderate increases in drug–gene interactions from these
sources (9,10). To help prevent regularly updated sources
from becoming outdated in the DGIdb, we have rewritten
and expanded online updaters to keep frequently updated
sources current within the database. With these more frequent, incremental updates to the DGIdb, there has been a
substantial increase in drug–gene interaction content from
IUPHAR’s Guide to Pharmacology and CIViC, a 23 and
200% increase, respectively (5,11). Additionally, a major update of DrugBank from version 4.3 to 5.0 was performed,
resulting in a 30% increase in interaction claims from this
source (12). Gene Ontology was also updated which provided a moderate increase for the druggable gene categories
(13). For this release, 18 493 new interaction claims were
added, of which 50% were from updated sources and 50%
from new sources. In total, there are now 6106 druggable
genes and 29 783 drug–gene interactions, which cover 41
100 genes and 9495 drugs, within the DGIdb.

The enhancements to the online updaters have also been
applied to Entrez Gene, from which 99% of all gene claims
made by the DGIdb constituent sources were grouped (Supplementary Figure S2) (3). Another major change from 2.0
to 3.0 is that the canonical drug source for the DGIdb has
switched from using PubChem compounds to ChEMBL
molecules (14). This switch has added 1.7 million ChEMBL
molecules to the database for potential matching to drug
claims. Importantly, switching to ChEMBL has added 195
antibody drugs (e.g. trastuzumab, cetuximab), a drug class
that is absent from the PubChem database and frequently
requested by users. These antibody drugs matched to 539
distinct drug claims from the constituent sources of the
DGIdb. With ChEMBL as the canonical drug source and
the improvements to the grouping strategy below, 80.2% of
all drug claims now group. Many of the resources we pull
from strive to be as comprehensive as possible, and sometimes include broad classes of drug or therapy (e.g. ‘hormone therapy’, ‘mtor inhibitors’, ‘chemotherapy’, ‘radiation’, ‘antibiotics’, etc.), which account for a large percentage of the remaining drug claims.
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abling grouping of drug claims with slightly different means
of joining multi-word terms (whitespace, dashes and underscores). Code has also been added to identify and remove
aliases that are highly ambiguous to improve exact matching of drug claims.
In addition to improved drug grouping, we have added interaction grouping, linking together interaction claims from
multiple sources that describe the exact same drug–gene interaction. The grouping efficiency for interactions is 75.2%.
The successful grouping of an interaction claim is dependent on the associated gene claims and drug claims successfully grouping. As a result, interaction grouping percentages are closely related to the grouping percentages for
drugs and genes (Supplementary Figure S2). The introduction of interaction groups has led to a noticeable improvement in response times on the UI for interaction searches,
even when query sizes and result sizes grow larger (Figure
2). Before interaction groups were created, searches in 2.0
had to query almost twice as many database tables as in 3.0.
Interaction groups allow for more efficient queries, which
leads to a 14-fold reduction in response times when searching the DGIdb.
We have expanded and added additional API endpoints
that now allow users to extract more information on the
drug–gene interactions provided by the DGIdb. These include endpoints to list all the interaction groups, gene
groups and drug groups in the DGIdb, as well as endpoints
to view detailed information about an individual interaction, gene or drug group. Drug/gene/interaction group
endpoints include various metadata about the group including its constituent claims. The information presented in the
interaction search results endpoint has been expanded to
include the Entrez and Chembl ID of the gene and drug
involved in an interaction, as well as a list of publications
that support each interaction. Users can also apply the preset filters to their interaction search through the API. This
brings the interaction search endpoint in sync with the user

interface. Moreover, the information presented in the interaction search results and the new individual endpoints for
interactions, genes and drugs more closely mirrors the views
available via the user interface. These new endpoints allow
users to more efficiently export all of the data available in
the DGIdb.

USER INTERFACE (UI) UPDATES
The 3.0 release of the DGIdb features a dramatic overhaul
of the UI that reflects many of the backend changes detailed
above. The search interactions page now allows the user to
apply the new preset filters in addition to the existing advanced filters (e.g. source databases, gene categories and interaction types) directly on the search form (Figure 3). On
performing a search, the user is redirected to the redesigned
search interactions results page, enabled by a new concept of
interaction groups instead of individual interaction claims.
This new view displays search results as lists of visually distinct panels for each search term mapped to gene or drug
groups. A list of uniquely matched terms is shown in one
tab whereas a second tab summarizes the list of ambiguously matched search terms and unmatched terms. Each
panel displays a table of interaction groups, along with summaries of the respective interaction types, sources, supporting publication PMIDs and a ranking. Users interested in
a particular interaction can navigate from the interaction
search results to the corresponding interaction group view.
Similarly, detailed information about an interacting gene or
drug can be found in the associated gene or drug group view
(Supplementary Figure S3). These new group views feature
(i) a summary tab, which details all relevant information collected from the various source claims (e.g. aliases, FDA approval status, supporting publications); (ii) an interactions
tab (for gene and drug group views), which lists summary
panels of each interaction in the DGIdb for this gene or
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Figure 1. DGIdb 3.0 content by source. The number of drug–gene interaction claims (first panel) and druggable gene categories (second panel) are
separated into three categories: sources that existed in the DGIdb previously, sources that existed in the DGIdb previously but have been updated for
3.0 or sources that are entirely new to the DGIdb. Abbreviations: CF: Clearity Foundation; CGI = Cancer genome interpreter, CKB = JAX-Clinical
Knowledgebase, CMI = Caris Molecular Intelligence, FO = Foundation One, GTP = Guide to pharmacology, MCG = My cancer genome, OncoKB =
Precision Oncology Knowledge Base, TALC = Targeted agents in lung cancer, TTD = Therapeutic Target Database, TEND = Trends in the exploration
of novel drug targets, GO = Gene Ontology and MSK = Memorial Sloan Kettering.

Nucleic Acids Research, 2018, Vol. 46, Database issue D1071

drug; and (iii) a claims tab with detailed information about
each claim supporting the group.
USAGE AND ACCESSIBILITY
The utility of the DGIdb as a resource is reflected in its substantial web and especially API traffic. The website receives
∼1700 unique users and ∼2800 sessions a month, an increase of 42 and 39%, respectively, since the initial release
of the DGIdb. Additionally, 42% of unique visitors within
the past year were returning users. Within the last year, the
DGIdb API has been used by 3689 unique IP addresses for
a total of 939 429 requests, as seen in Supplementary Figure
S4. At the time of publication, 2.0 was used by a number of
bioinformatics tools in the development of their platforms.
DGIdb has since been integrated into four additional tools,
bringing the total number of known platforms that utilize
the DGIdb to 10. These platforms are GeneCards (http:
//www.genecards.org), CVE (20), rDGIdb (21), PANDA
(22), iCAGES (icages.usc.edu), BioGPS (23), Omics Pipe
(24), GEMINI (25), StationX (www.stationxinc.com) and
IHLDB.rf (www.lungcancerdatabase.com). These integrations highlight the accessibility and utility of the DGIdb
API, which has been expanded to include new endpoints
in 3.0.
To handle the increasing usage of the DGIdb, the
database backend has undergone significant updates. One
of the most notable is the upgrade from Rails 3 to the Rails 5
framework. We also added 22 new tables to the PostgreSQL
database schema consisting of 2 326 676 records supporting the described changes and added 4065 new lines of code
to the repository, an expansion of the codebase by 18.9%.
This activity can be seen through the commit history to the
GitHub repository in Supplementary Figure S5. For access
to this code and data, please see the availability section below.
The open source DGIdb software was previously available under the GNU General Public License 3.0 (GPL3)
and has been re-released under the more permissive MIT

license. The data contained within the DGIdb are available under the licenses assigned by their host sources which
makes it possible to integrate the DGIdb into any workflow.
Since 2.0, the database has moved from being hosted on a
local server to being hosted on Amazon Web Services. With
this change in server host, the availability of the DGIdb
has been expanded through the release of two Amazon Machine Images, a development environment and production
environment. By providing this production environment for
users, we now support a quick-start solution for private,
cloud-based applications.
CONCLUSION AND FUTURE DIRECTIONS
DGIdb 3.0 has undergone significant changes. The number of drug–gene interactions and druggable genome definitions has been substantially expanded through the updating
of existing sources and inclusion of new sources. To improve
searches, we have included preset filters that allow searches
for commonly requested gene or drug classes. To utilize
these filters, a more intuitive UI was created and new fields
to the database schema were added. Additionally, there are
new ways to both access the data within the DGIdb and to
deploy local or cloud instances of the database.
While the DGIdb remains a powerful resource for querying drug–gene interactions, we anticipate future changes
that will improve the user experience and the content within
it. One change is that claim information will be linked to the
licensing terms from constituent sources through the various methods of accessing the DGIdb including the web interface, API endpoints and data downloads. Second, while
grouping statistics for claims have improved in the DGIdb
3.0, there are still a significant percentage of claims that remain ungrouped. To address this, the drug grouper will need
to be optimized to handle the exceptions that currently prevent successful grouping. Third, much of the user interface
is a series of static renders by the server. A potential future
enhancement is a more reactive, client-side web application
that would allow for more dynamic visualization and exploration of the data. Finally, other databases (e.g. CIViC)
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Figure 2. Comparison of the DGIdb 2.0 and 3.0 response time by search and result size. The left panel summarizes observed response times (n = 100)
for searches of various sizes (1, 2, 3, 4, 5, 10, 15, 20 and 25) of randomly selected genes. The right panel summarizes observed response times for the
corresponding interaction search result sizes.
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Figure 3. The DGIdb interaction search interface. (A) A search field accepts drug or gene identifiers, depending on which tab is selected and provides autocompletion suggestions for search terms. (B) Preset options are provided to filter search results based on the attributes of mapped interactors. (C) Advanced
filters allow the user to further filter based on source database, gene category or interaction type. (D) The interaction search results (Unique Matches) view
shows results for search terms that were matched within the DGIdb. (E) The interaction search results (Ambiguous or Unmatched) view shows search
terms that were either ambiguously matched or unmatched within the DGIdb. (F) Additional side panels provide a brief summary of unmatched and
ambiguously matched terms.
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have had success utilizing a community curation model. In
an effort to enable community feedback to address the complexity of grouping and representing drug–gene interaction
data, the DGIdb will be moved to a similar model. Expected changes include users creating login accounts, suggesting sources or claims for inclusion and verification that
a source or claim has enough support to be included within
the DGIdb. These changes will require significant code updates but will greatly increase the utility of the DGIdb.

DGIdb is an open access database and web interface (www.dgidb.org) with open source code available
on GitHub (https://github.com/griffithlab/dgi-db). We also
provide data downloads for drug claims, gene claims, and
interaction claims on the website in addition to a SQL data
dump (http://dgidb.org/downloads). Information about the
API and its endpoints can also be found on the website
(http://dgidb.org/api).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
National
Human
Genome
Research
Institute
[R00HG007940 to M.G.]; National Cancer Institute
[K22CA188163 to O.L.G., T32CA113275, F32CA206247
to A.H.W, T32CA113275 to K.C.C., U01CA209936];
National Institute of General Medical Sciences
[5R25GM103757]. Funding for open access charge:
National Institutes of Health [R00HG007940].
Conflict of interest statement. None declared.
REFERENCES
1. Griffith,M., Griffith,O.L., Coffman,A.C., Weible,J.V.,
McMichael,J.F., Spies,N.C., Koval,J., Das,I., Callaway,M.B.,
Eldred,J.M. et al. (2013) DGIdb––mining the druggable genome.
Nat. Methods, 10, 1209–1210.
2. Wagner,A.H., Coffman,A.C., Ainscough,B.J., Spies,N.C.,
Skidmore,Z.L., Campbell,K.M., Krysiak,K., Pan,D.,
McMichael,J.F., Eldred,J.M. et al. (2016) DGIdb 2.0: mining
clinically relevant drug–gene interactions. Nucleic Acids Res., 44,
D1036–D1044.
3. Brown,G.R., Hem,V., Katz,K.S., Ovetsky,M., Wallin,C.,
Ermolaeva,O., Tolstoy,I., Tatusova,T., Pruitt,K.D., Maglott,D.R.
et al. (2015) Gene: a gene-centered information resource at NCBI.
Nucleic Acids Res., 43, D36–D42.
4. Kim,S., Thiessen,P.A., Bolton,E.E., Chen,J., Fu,G., Gindulyte,A.,
Han,L., He,J., He,S., Shoemaker,B.A. et al. (2016) PubChem
substance and compound databases. Nucleic Acids Res., 44,
D1202–D1213.
5. Griffith,M., Spies,N.C., Krysiak,K., McMichael,J.F., Coffman,A.C.,
Danos,A.M., Ainscough,B.J., Ramirez,C.A., Rieke,D.T., Kujan,L.
et al. (2017) CIViC is a community knowledgebase for expert
crowdsourcing the clinical interpretation of variants in cancer. Nat.
Genet., 49, 170–174.
6. Chakravarty,D., Gao,J., Phillips,S., Kundra,R., Zhang,H., Wang,J.,
Rudolph,J.E., Yaeger,R., Soumerai,T., Nissan,M.H. et al. (2017)
OncoKB: a precision oncology knowledge base. JCO Precis. Oncol.,
1, doi:10.1200/PO.17.00011.

Downloaded from https://academic.oup.com/nar/article-abstract/46/D1/D1068/4634012 by guest on 15 November 2019

AVAILABILITY

7. Patterson,S.E., Liu,R., Statz,C.M., Durkin,D., Lakshminarayana,A.
and Mockus,S.M. (2016) The clinical trial landscape in oncology and
connectivity of somatic mutational profiles to targeted therapies.
Hum. Genomics, 10, 4.
8. Finan,C., Gaulton,A., Kruger,F.A., Lumbers,R.T., Shah,T.,
Engmann,J., Galver,L., Kelley,R., Karlsson,A., Santos,R. et al.
(2017) The druggable genome and support for target identification
and validation in drug development. Sci. Transl. Med., 9, eaag1166.
9. Yeh,P., Chen,H., Andrews,J., Naser,R., Pao,W. and Horn,L. (2013)
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment
(DIRECT): a catalog of clinically relevant cancer mutations to enable
genome-directed anticancer therapy. Clin. Cancer Res., 19,
1894–1901.
10. Simon,G.R. and Somaiah,N. (2014) A tabulated summary of targeted
and biologic therapies for non-small-cell lung cancer. Clin. Lung
Cancer, 15, 21–51.
11. Southan,C., Sharman,J.L., Benson,H.E., Faccenda,E., Pawson,A.J.,
Alexander,S.P.H., Buneman,O.P., Davenport,A.P., McGrath,J.C.,
Peters,J.A. et al. (2016) The IUPHAR/BPS Guide to
PHARMACOLOGY in 2016: towards curated quantitative
interactions between 1300 protein targets and 6000 ligands. Nucleic
Acids Res., 44, D1054–D1068.
12. Law,V., Knox,C., Djoumbou,Y., Jewison,T., Guo,A.C., Liu,Y.,
Maciejewski,A., Arndt,D., Wilson,M., Neveu,V. et al. (2014)
DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids
Res., 42, D1091–D1097.
13. Gene Ontology Consortium (2015) Gene Ontology Consortium:
going forward. Nucleic Acids Res., 43, D1049–D1056.
14. Bento,A.P., Gaulton,A., Hersey,A., Bellis,L.J., Chambers,J.,
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